\
&
Contact us
\
&
Contact us
COST plays an important role in the development of the European research area. COST's mission is to strengthen Europe in scientific and technological research through the support of European cooperation and interaction between European researchers.
Under Horizon Europe COST will be fully funded by the Widening and ERA part and is one of the widening actions to help EU countries that are lagging behind to stimulate their participation in Horizon Europe through scientific networking.
These networks, in the form of COST Actions, can be in any scientific field and are open to all type of actors (academia, public institutions, SMEs, Companies, etc.). A typical COST Action runs for four years and has an average budget of 134,500 EUR per year.
The funding is limited to networking activities (meetings, conferences, seminars, workshops) and the organisation of exchange activities (scientific exchanges of short duration, training schools, publications and dissemination activities). The actual research is funded via other (national or regional) channels.
There are mainly two ways to engage with COST:
In Flanders, FWO is the first Contact Point for any questions related to the COST Programme. For more information on COST please visit the FWO website.
manhei.to@fwo.be
+32 2 550 15 55
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents contain additional information related to this programme, and are similar to related links.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
